Accelerate Diagnostics Inc (AXDX) Director Jack W. Schuler Buys 15,000 Shares
Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler bought 15,000 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was bought at an average cost of $25.15 per share, for a total transaction of $377,250.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Accelerate Diagnostics Inc (NASDAQ AXDX) traded up $0.60 during trading on Monday, reaching $25.85. The company’s stock had a trading volume of 220,864 shares, compared to its average volume of 284,409. The company has a market capitalization of $1,430.00, a P/E ratio of -21.91 and a beta of 2.22. Accelerate Diagnostics Inc has a twelve month low of $16.75 and a twelve month high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings results on Thursday, February 15th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative return on equity of 55.26% and a negative net margin of 1,520.99%. equities analysts expect that Accelerate Diagnostics Inc will post -1.2 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Accelerate Diagnostics by 1.1% during the fourth quarter. BlackRock Inc. now owns 1,683,028 shares of the medical research company’s stock valued at $44,095,000 after purchasing an additional 17,848 shares in the last quarter. Vanguard Group Inc. increased its position in Accelerate Diagnostics by 6.7% during the second quarter. Vanguard Group Inc. now owns 1,237,174 shares of the medical research company’s stock valued at $33,837,000 after acquiring an additional 77,753 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its position in Accelerate Diagnostics by 8.6% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 934,252 shares of the medical research company’s stock valued at $24,477,000 after acquiring an additional 73,770 shares during the last quarter. Next Century Growth Investors LLC increased its position in Accelerate Diagnostics by 30.5% during the fourth quarter. Next Century Growth Investors LLC now owns 660,020 shares of the medical research company’s stock valued at $17,292,000 after acquiring an additional 154,387 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS increased its position in Accelerate Diagnostics by 37.3% during the third quarter. Kornitzer Capital Management Inc. KS now owns 530,219 shares of the medical research company’s stock valued at $11,903,000 after acquiring an additional 144,055 shares during the last quarter. 44.93% of the stock is currently owned by hedge funds and other institutional investors.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.